News

Arriva Pharmaceuticals Granted Fusion Protein Patent - Intellectual property provides strong position for development of therapy for asthma.
Dated: 21 May 2008
Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema.
Dated: 28 February 2008